Candida albicans is the most common human fungal pathogen, causing infections that
range from mucous membranes to systemic infections. The present article provides an …

Highlights•Our limited arsenal of antifungals is threatened by drug-resistant fungal
pathogens.•Inherent resistance is when all strains of a species show antifungal …

The high rates of morbidity and mortality caused by fungal infections are associated with the
current limited antifungal arsenal and the high toxicity of the compounds. Additionally …

Candida albicans is the most common human fungal pathogen causing diseases ranging
from mucosal to systemic infections. As a commensal, C. albicans asymptomatically …

The use of antifungal drugs in the therapy of fungal diseases can lead to the development of
antifungal resistance. Resistance has been described for virtually all antifungal agents in …

Antifungal therapy is a central component of patient management for acute and chronic
mycoses. Yet, treatment choices are restricted because of the sparse number of antifungal …

The epidemiology of Candida infections has changed in recent years. Although Candida
albicans is still the main cause of invasive candidiasis in most clinical settings, a substantial …

Fungicides are widely used in developed agricultural systems to control disease and
safeguard crop yield and quality. Over time, however, resistance to many of the most …

Terbinafine is one of the allylamine antifungal agents whose target is squalene epoxidase
(SQLE). This agent has been extensively used in the therapy of dermatophyte infections …

Candida auris is an emerging multi-drug resistant yeast, that causes major issues regarding
patient treatment and surface disinfection in hospitals. Indeed, an important proportion of C …